ripekg:author/RIPEAU70E13D455FA1BA52Jean‐charles Schwartz |
rdf:type |
node1 |
ripekg:author/RIPEAU70E13D455FA1BA52Jean‐charles Schwartz |
rdf:type |
rdfs:Resource |
ripekg:author/RIPEAU70E13D455FA1BA52Jean‐charles Schwartz |
rdf:type |
owl:Thing |
ripekg:author/RIPEAU70E13D455FA1BA52Jean‐charles Schwartz |
rdf:type |
prov:Person |
ripekg:author/RIPEAU70E13D455FA1BA52Jean‐charles Schwartz |
rdf:type |
foaf:Person |
ripekg:author/RIPEAU70E13D455FA1BA52Jean‐charles Schwartz |
rdf:type |
ripe:AuthorAuthor |
ripekg:author/RIPEAU70E13D455FA1BA52Jean‐charles Schwartz |
owl:sameAs |
https://semopenalex.org/author/A5107824762 |
ripekg:author/RIPEAU70E13D455FA1BA52Jean‐charles Schwartz |
foaf:familyName |
Schwartz |
ripekg:author/RIPEAU70E13D455FA1BA52Jean‐charles Schwartz |
foaf:givenName |
Jean‐charles |
ripekg:author/RIPEAU70E13D455FA1BA52Jean‐charles Schwartz |
foaf:name |
Jean‐charles Schwartz |
ripekg:work/10.1111%2Fjsr.14373Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by <scp>CPAP</scp>: Randomised phase 3 study |
dcterms:creator |
ripekg:author/RIPEAU70E13D455FA1BA52Jean‐charles Schwartz |